News | IFM Therapeutics

IFM Therapeutics

News

Mar 13, 2024

Novartis Acquires IFM Due to Develop First-In-Class STING Antagonist Program Targeting Innate Immune System

Dec 01, 2021

IFM Therapeutics Announces Extension of Collaboration Agreement for cGAS-STING Subsidiary, IFM Due

Apr 12, 2021

New Review Examines the cGAS–STING Pathway as a Therapeutic Target in Inflammatory Diseases

Dec 01, 2020

IFM Therapeutics Named 2020 Scrip Awards Finalist

Sep 28, 2020

IFM Due Co-Founder Andrea Ablasser, M.D., Named Recipient of 2020 William B. Coley Award

Jun 03, 2020

IFM Therapeutics Welcomes Two New Leadership Team Members

Jan 07, 2020

IFM Therapeutics Appoints Michael Cooke, Ph.D., as Chief Scientific Officer

Dec 02, 2019

IFM Therapeutics Announces $55.5 Million Financing to Launch and Fund New Subsidiaries and Appointment of Dr. H. Martin Seidel as Chief Executive Officer

Nov 20, 2019

New Research Demonstrates Second Direct Link Between Inflammasome Activation and Alzheimer’s Disease

Sep 12, 2019

IFM Therapeutics Named Winner in the Startup Category at 2019 Xconomy Awards

Media Contact Image Mobile

Media Contact

Michael Sullivan
Spectrum Science
503-799-7520
msullivan@spectrumscience.com